NEWS RELEASES
The information contained in each news release on this page was factually accurate on the date it was issued and posted.
Sutro Biopharma Reports Full Year 2020 Financial Results and Provides Business Highlights and 2021 Anticipated Milestones
- Year-end 2020 cash, cash equivalents and marketable securities of $326.5 million, with projected runway into the second half of 2023 - Four antibody-drug conjugate programs are now in the clinic that were discovered through Sutro’s proprietary and integrated...
Sutro Biopharma to Participate in the Cowen 41st Annual Healthcare Conference
SOUTH SAN FRANCISCO, Calif., Feb. 23, 2021 – Sutro Biopharma, Inc. (NASDAQ: STRO), a clinical-stage drug discovery, development and manufacturing company focused on the application of precise protein engineering and rational design to create next-generation cancer and...
Sutro Biopharma Announces First Patient Dosed in the Dose-Expansion Study of STRO-002 in Patients with Ovarian Cancer
SOUTH SAN FRANCISCO, Calif., Jan. 21, 2021 – Sutro Biopharma, Inc. (NASDAQ: STRO), a clinical-stage drug discovery, development and manufacturing company focused on the application of precise protein engineering and rational design to create next-generation cancer and...
Sutro Biopharma to Present at the 39th Annual J.P. Morgan Virtual Healthcare Conference
SOUTH SAN FRANCISCO, Calif., Jan. 5, 2021 – Sutro Biopharma, Inc. (NASDAQ: STRO), a clinical-stage drug discovery, development and manufacturing company focused on the application of precise protein engineering and rational design to create next-generation cancer and...
Sutro Biopharma Announces Closing of Upsized $144.9 Million Public Offering, including Full Exercise of the Underwriters’ Option to Purchase Additional Shares
South San Francisco, Calif., Dec. 11, 2020 – Sutro Biopharma, Inc. (Nasdaq: STRO), a clinical-stage drug discovery, development and manufacturing company focused on the application of precise protein engineering and rational design to create next-generation cancer and...
Sutro Biopharma Announces Pricing of $126.0 Million Public Offering
South San Francisco, Calif., Dec. 8, 2020 -- Sutro Biopharma, Inc. (Nasdaq: STRO), a clinical-stage drug discovery, development and manufacturing company focused on the application of precise protein engineering and rational design to create next-generation cancer and...
Sutro Biopharma Announces Proposed Public Offering of 5 Million Shares of Common Stock
South San Francisco, Calif., Dec. 7, 2020 -- Sutro Biopharma, Inc. (Nasdaq: STRO), a clinical-stage drug discovery, development and manufacturing company focused on the application of precise protein engineering and rational design to create next-generation cancer and...
Sutro Biopharma Presents Data from Ongoing Phase 1 Dose-Escalation Study for STRO-001 for the Treatment of B-cell Non-Hodgkin Lymphoma at the 62nd American Society of Hematology Annual Meeting
- STRO-001 was generally well-tolerated in patients with late-line NHL with no ocular or neuropathy toxicity signals; MTD has not been reached - - 1 CR & 2 PRs observed in heavily pretreated patients with DLBCL; 1 SD in marginal zone lymphoma; 2 SDs in follicular...
Sutro Biopharma Announces Encouraging Interim Data on STRO-002 Phase 1 Dose-Escalation Study for Patients with Ovarian Cancer
- Responses observed in 32% (10/31) of evaluable patients treated at clinically active dose levels–including 1 CR, 3 cPRs and 6 uPRs - - Disease control rate at 12 weeks is 74% (23/31) and 10 patients remained on treatment - - Dose-expansion has been intiated to...
Sutro Biopharma Announces Appointment of Jon M. Wigginton, M.D., to Board of Directors
- Dr. Wigginton, leader in immuno-oncology and CMO at Cullinan Oncology, to bring additional strategic expertise to Sutro’s Board - SOUTH SAN FRANCISCO, Calif., Dec. 1, 2020 – Sutro Biopharma, Inc. (NASDAQ: STRO), a clinical-stage drug discovery, development and...